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The clinical significance of ERBB2 amplification/overexpression in gastric cancer remains unclear. In this study, we evaluated the
ERBB2 status in 463 gastric carcinomas using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH), and
compared the findings with histopathological characteristics and with disease-specific survival. ERBB2 overexpression (2þ and 3þ)
and amplification (ratio ERBB2/CEP17X2) were found in 43 (9.3%) and 38 (8.2%) gastric carcinomas, respectively. Perfect IHC/FISH
correlation was found for the 19 cases scored as 0 (all negative by FISH), and also for the 25 cases scored as 3þ (all positive by
FISH). One out of six carcinomas scored as 1þ and 12 out of 18 carcinomas scored as 2þ were positive by FISH. ERBB2
amplification was associated with gastric carcinomas of intestinal type (P¼0.007) and with an expansive growth pattern (P¼0.021).
ERBB2 amplification was detected in both histological components of two mixed carcinomas, indicating a common clonal origin.
A statistically significant association was found between ERBB2 amplification and worse survival in patients with expansive gastric
carcinomas (P¼0.011). We conclude that ERBB2 status may have clinical significance in subsets of gastric cancer patients, and that
further studies are warranted to evaluate whether patients whose gastric carcinomas present ERBB2 amplification/overexpression
may benefit from therapy targeting this surface receptor.
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Despite the trend for decreasing incidence, gastric adenocarcino-
ma is still the second cause of cancer death worldwide (Parkin
et al, 2005). The overall 5-year survival rate of patients with
resectable gastric cancer ranges from 10 to 30% (Harrison et al,
1998; Msika et al, 2000; Green et al, 2002). Apart from surgical
resection, evaluation of available therapies, both neo-adjuvant and
adjuvant, provides conflicting results regarding the clinical
outcome. Several meta-analyses have been published in an attempt
to address the discrepancies reported in the literature, but
recommendation for adjuvant chemotherapy in Western centres
is still not consensual (Hermans et al, 1993; Earle and Maroun,
1999; Mari et al, 2000; Gianni et al, 2001; Janunger et al, 2001, 2002;
Hu et al, 2002). The most important prognostic factor established
for gastric cancer is the TNM stage, which is determined by the
depth of invasion, involvement of lymph nodes, and distant
metastasis. However, clinical outcome varies among patients in the
same stage (Park et al, 2006). Therefore prognostic factors other
than the TNM stage, as well as new therapies, would be of great
value for gastric cancer patients.
The ERBB2 gene maps to 17q12–q21 and encodes a 185-kDa
transmembrane tyrosine kinase receptor (p185), which is a
member of the epidermal growth factor receptor family (Xu
et al, 1984; Akiyama et al, 1986; Popescu et al, 1989). In breast
carcinomas, ERBB2 functions as an oncogene, as amplification of
the gene induces protein overexpression in the cell membrane
(Slamon et al, 1989). Besides being a poor prognosis marker
(Dowsett et al, 2003), ERBB2 amplification is a predictive marker
for targeted therapy with the monoclonal antibody trastuzumab in
breast cancer patients with metastatic disease (Slamon et al, 2001).
More recently, trastuzumab was shown to be effective as adjuvant
treatment in breast-carcinoma patients with ERBB2 amplification/
overexpression (Piccart-Gebhart et al, 2005; Romond et al, 2005).
Apart from breast cancer, ERBB2 amplification has been found
in other malignant tumours, such as ovarian (McKenzie et al,
1993), lung (Hirashima et al, 2001), colon (Cohen et al, 1989), and
gastric carcinomas (David et al, 1992). Earlier studies in gastric
carcinomas reported ERBB2 overexpression using immunohisto-
chemistry (IHC) in 5.2–22.6% of the cases, whereas the proportion
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swith ERBB2 amplification evaluated using fluorescence in situ
hybridisation (FISH) ranged from 3.8 to 12.2% (Takehana et al,
2002; Varis et al, 2004; Park et al, 2006; Kim et al, 2007). However,
the clinical significance of ERBB2 amplification/overexpression in
gastric cancer patients is still not clear, because most studies had
neither follow-up data nor statistical power for that purpose
(David et al, 1992; Nakajima et al, 1999; Takehana et al, 2002;
Kimura et al, 2004; Kim et al, 2007).
Recently, Tanner et al (2005) showed that the gastric-cancer cell
line N87 presenting ERBB2 amplification is as sensitive to
trastuzumab as the ERBB2-amplified breast-carcinoma cell line
SKBR-3, which is a widely used reference in trastuzumab
sensitivity studies (Pegram et al, 1997, 1999). Furthermore,
Rebischung et al (2005) reported a case of a gastric cancer patient
with ERBB2 overexpression (3þ) who responded to a combina-
tion of chemotherapy and trastuzumab. A large-scale clinical study
is currently being carried out to compare the response to
chemotherapy combined with trastuzumab vs chemotherapy alone
in gastric carcinoma patients with ERBB2 amplification.
To clarify the potential clinical relevance of ERBB2 status in
gastric cancer, we have characterised its overexpression and
amplification in 463 patients with clinicopathological data and a
follow-up time of 6–10 years.
MATERIALS AND METHODS
Type of study and selection of participants
A two-step study design was used to select the gastric cancer
patients. First, a cross-sectional study was used to select 463
consecutive primary gastric adenocarcinoma patients who under-
went gastrectomy at the Portuguese Oncology Institute—Porto
(between 1996 and 2000) to assess the frequency of ERBB2
overexpression and amplification. Simultaneously, the first step
selected patients with ERBB2 amplification for the second step,
resulting in a retrospective prognostic cohort study (follow-up
time from 1 to 133 months, mean 52.8 months), which included all
patients with ERBB2 amplification (n¼38) and randomly selected
patients with no amplification (n¼218).
The tissue specimens for IHC and FISH analyses were archival
tumour samples of surgically resected gastric carcinomas from the
463 patients. Patient age at diagnosis ranged from 26 to 91 years
(median, 67 years).
Variables
Clinical data were collected by a group of clinicians blinded to
ERBB2 status, using a datasheet specifically developed for this
study, including the following parameters: age, gender, date of and
status on last follow-up, surgery type (curative or palliative
according to the surgeon) and date, TNM stage, and treatment
other than surgery (if any). Time to clinical outcome was
considered from the date of surgery until the last clinical
appointment attended, and each patient was classified under one
of the following categories: alive with no evidence of disease, alive
with disease, dead with no evidence of disease, and dead from
disease. For histological data collection, pathologists reviewed a
representative H&E-stained slide.
Immunohistochemistry
Immunohistochemistry targeting the ERBB2 protein was carried
out in 4-mm-thick tissue sections. The monoclonal antibody NCL-
CB11 (mouse monoclonal antibody, Novocastra Laboratories Ltd,
Newcastle upon Tyne, UK), recognising the intracellular portion of
the protein, was used. Tissue sections were deparaffinised followed
by antigen retrieval in citrate buffer (0.01 M, pH 6.0) at high
temperature (water bath at 981C). After blocking for non-specific
binding, the primary antibody was added in a pre-standardised
dilution (1 out of 60), and incubated for 30min at room
temperature. A standard avidin–biotin–peroxidase complex
technique was used for visualisation, with diaminobenzidine as
chromogen (UltraVision Detection System Anti-Polyvalent, HRP/
DAB Ready-To-Use, LabVision Corporation, Fremont, CA, USA).
The tissue sections were then lightly counterstained with
haematoxylin and cover-slipped.
The following scoring system was used: score 0, no membrane
staining or o10% of cells stained; 1þ, incomplete membrane
staining in 410% of the cells; 2þ, weak to moderate complete
membrane staining 410% of the cells with; and 3þ, strong and
complete membrane staining in 410% of the cells. An appropriate
positive control (ERBB2-overexpressing breast carcinoma) was
included in each run and each section was analysed by a
pathologist.
Fluorescence in situ hybridisation
From each gastric adenocarcinoma sample, 4-mm-thick sections of
a representative tissue block were cut onto SuperFrost Plus
adhesion slides. The slides were then deparaffinised in two series
of xylol followed by two series of ethanol (8min each), rinsed in
2 SSC, and placed in a solution of NaS/CN 1 M at 801C for 10min.
The tissue was then digested with 6mgml
 1 pepsin for 22min at
371C, after which the slides were rinsed in 2 SSC and dehydrated
in an ethanol series. To assess ERBB2 amplification, a commercial
probe (QBiogene, Montreal, Canada now MP Biomedicals, Irvine,
CA, USA) targeting ERBB2, direct-labelled with rhodamine, and a
control probe for chromosome 17 centromere (CEP17), direct-
labelled with fluorescein, were used. The slides and probes were
placed in a HYBrite denaturation/hybridisation system and
co-denatured at 801C for 7min. Hybridisation carried out for
18h at 371C, followed by post-hybridisation washes in 2 SSC/
0.5% Igepal at 731C for 5min and 2 SSC/0.1% Igepal at room
temperature, after which slides were counterstained with DAPI.
Fluorescent images were sequentially captured with a Cohu 4900
CCD camera, using an automated filter wheel coupled to a Zeiss
Axioplan fluorescence microscope and a CytoVision system.
Gene amplification was scored when a minimum of 60 cancer
cell nuclei exhibited a ratio ERBB2/CEP17 Z2, or when an ERBB2
signal cluster was observed.
Statistical analysis
Categorical data were analysed using w
2-square test. For para-
metric data, Student’s t-test was used when comparing two means.
Survival curves were calculated according to the Kaplan–Meier
method. Cases lost to follow-up and deaths caused by reasons
other than gastric cancer were censored during survival analysis.
The significance of differences between survival curves was
determined using the log-rank or Breslow’s tests. All statistical
analyses were conducted using SPSS v.15 (SPSS, Chicago, IL, USA).
RESULTS
Overexpression of ERBB2 protein
The ERBB2 protein status was determined by IHC for the 463
gastric carcinoma tissues (Figure 1). In all, 414 were classified as
score 0 (89.4%), 6 were classified as score 1þ (1.3%), 18 were
classified as score 2þ (3.9%), and 25 were classified as score 3þ
(5.4%).
ERBB2 gene amplification
Fluorescence in situ hybridisation analysis was performed in all
cases (n¼43) in which IHC showed complete membrane
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simmunostaining (2þ and 3þ). In addition, 25 cases (including all
six 1þ cases) that were regarded as negative for ERBB2
overexpression by IHC were also analysed by FISH. Gene
amplification was detected in 38 gastric carcinomas (Figure 2).
Only one of the 25 tumours showing negative immunostaining
(scored as þ1) exhibited ERBB2 amplification (Figure 2). On the
other hand, all 25 cases showing strong complete membrane
immunostaining (3þ) exhibited ERBB2 amplification. Among the
18 tumours with 2þ immunostaining, 12 (66.6%) showed
amplification (Figure 2). Of the remaining 2þ cases, four showed
chromosome 17 polysomy and two showed no genetic alteration.
Correlation between ERBB2 amplification and
clinicopathological findings
Table 1 shows the clinicopathological differences observed
between gastric carcinomas with or without ERBB2 amplification.
Most gastric carcinomas showing ERBB2 amplification were of the
intestinal/glandular type (81.6% of all positive cases, P¼0.007),
but this genetic alteration was also observed in diffuse/isolated
cells, and solid and mixed carcinomas (7.9, 5.3, and 5.3% of
positive cases, respectively). Two mixed carcinomas showed
ERBB2 amplification and overexpression in the two histological
components (Figure 1). ERBB2 amplification was also associated
with an expansive growth pattern (P¼0.021). Venous invasion,
assessed through orcein staining, was not associated with ERBB2
amplification. No differences were observed between ERBB2-
amplified and ERBB2 non-amplified cases in terms of age, gender,
type of surgery, and clinical stage.
Survival analysis
Survival analysis was performed on 256 patients, including all
38 who showed ERBB2 amplification. Patients with ERBB2
amplification had in general, worse 10-year survival rates than
those without this genetic alteration (35.3 vs 43.2%, respectively;
Figure 3), although the difference was not statistically significant
(P¼0.222).
Differences in survival were more evident when we compared
similar subgroups of patients. Patients with expansive gastric
carcinoma and ERBB2 amplification had a statistically significant
worse survival than those without this genetic alteration (Figure 3;
P¼0.011). No such difference was seen in patients with infiltrative
gastric carcinoma (P¼0.863). Among patients with no lymph node
metastases, those with ERBB2-amplified carcinomas had a trend
for worse survival when compared with those without this genetic
alteration (P¼0.085).
DISCUSSION
The assessment of ERBB2 status is essential for efficient selection
of patients who might benefit from targeted therapy with
trastuzumab or other drugs targeting this surface receptor. This
therapeutic option proved useful in extending the survival of
breast cancer patients, particularly when selected by FISH (Mass
et al, 2005). Since then, interest in applying this approach to other
malignancies with ERBB2 amplification has increased. The first
goal of this study was to clarify the frequency of ERBB2
overexpression and amplification in a large series of gastric
carcinoma patients (n¼463). The patients in whom ERBB2
amplification was found (n¼38), as well as 218 ERBB2-negative
patients, were selected for survival analysis. Using clinicopatho-
logical and follow-up data from these 256 patients, we investigated
whether ERBB2 amplification is a prognosis factor in different
subgroups of gastric cancer patients. Given the nature of
the biological material used in this study (formalin-fixed,
paraffin-embedded archival tissue), the techniques chosen to
Figure 1 ERBB2 protein expression evaluated by IHC in gastric carcinomas. (A) Negative ERBB2 expression (0) (original magnification  400);
(B) ERBB2 positive expression –(3þ) (original magnification  400); (C) mixed type carcinoma with ERBB2 overexpression in both histological
components (original magnification  100).
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sassess ERBB2 protein overexpression (IHC) and ERBB2 amplifica-
tion (FISH) are the most appropriate to ensure reliable and
reproducible results. Moreover, both techniques allow for the
specific detection of ERBB2 alteration in individual cells, while
maintaining critical architectural tissue information (Pauletti et al,
2000).
Both overexpression (9.3%) and amplification (8.2%) frequen-
cies observed in the current study are within the range reported
in earlier reports. There was a perfect correlation between IHC
and FISH findings in cases with strong (3þ) complete membrane
staining (100%), as well as in those scored as 0. Kim et al (2007)
reported 22.6% of carcinomas overexpressing ERBB2 protein
(2þ or 3þ), but only 7.7% showed gene amplification. As in our
study, the correlation was higher in cases with strong (3þ)
membrane staining and in those scored as 0. Takehana et al (2002)
also found ERBB2 amplification in all gastric carcinoma cases
scored as 3þ. On the other hand, Park et al (2006) found ERBB2
amplification in only 45% of the carcinomas scored as 3þ, which
might be due to the low specificity of the antibody used. In this
study, one of the six gastric carcinomas classified as 1þ showed
ERBB2 amplification. Similarly, Kim et al (2007) found ERBB2
amplification in 4% of the 1þ gastric carcinomas analysed by
FISH. Most of the studies that reported the absence of gene
amplification in carcinomas classified as 1þ did not analyse all
1þ carcinomas (Takehana et al, 2002; Park et al, 2006). As for the
18 gastric carcinomas classified as 2þ in this study, 12 (66.6%)
showed ERBB2 amplification and four of the remaining six
presented chromosome 17 polisomy. The correlation between
2þ carcinomas and ERBB2 amplification is higher than usually
reported in the literature, possibly because of better specificity of
the antibody. In the light of our observations, as well as data from
the literature, we recommend that all cases classified by IHC
as 1þ and 2þ should be analysed by FISH to avoid false negatives
and false positives, respectively.
Some genetic alterations are exclusive of given subtypes of
gastric carcinomas, as exemplified by CDH1 mutations in diffuse
gastric carcinomas (Becker et al, 1994; Grady et al, 2000). Several
authors have earlier stated that ERBB2 amplification is an
exclusive event of intestinal-type gastric carcinomas (Takehana
et al, 2002; Varis et al, 2004). However, of the 38 carcinomas with
amplification detected by FISH, three were diffuse and four were
not classifiable by Lauren. Other authors reported that diffuse
gastric carcinomas account for 5–6.2% of all ERBB2-amplified
carcinomas (Tanner et al, 2005; Park et al, 2006; Kim et al, 2007),
which is corroborated by our findings. Interestingly, in both
Western and Eastern patients there is a correlation between gastric
carcinomas with ERBB2 amplification and intestinal type: 81.6% in
this study vs 86 and 84.2% reported in Eastern patients (Park et al,
2006; Kim et al, 2007).
In two mixed gastric carcinomas containing both isolated cells
and glandular components (Carneiro, 1997), ERBB2 overexpres-
sion and amplification were found in both histological patterns.
These data indicate that the two histological counterparts of a
carcinoma have the same clonal origin and that ERBB2 amplifica-
tion is an early genetic alteration acquired before other genetic
and/or epigenetic alterations associated with the phenotypic
divergence in these cases. This hypothesis is supported by
Carvalho et al (2006), who studied by array-comparative genome
hybridisation 12 mixed carcinomas. Besides finding no significant
differences between different histological components of the same
tumour, one of the mixed gastric carcinomas studied presented
ERBB2 amplification in both histological counterparts. Further-
more, in our consecutive series of gastric cancer patients, we found
ERBB2 amplification in two early gastric carcinomas (stage IA),
Figure 2 Fluorescence in situ hybridisation targeting ERBB2 in gastric carcinoma specimens (original magnification,  1000). Red labelled probes target the
ERBB2, green labelled probes target chromosome 17 centromere, and nuclei (blue) are stained with DAPI. (A) intestinal type carcinoma (score 0 by IHC)
with no ERBB2 amplification; (B) intestinal type carcinoma (score 2þ by IHC) showing ERBB2 amplification; (C) intestinal type carcinoma (score 1þ by
IHC) showing ERBB2 amplification. A full colour version of this figure is available at the British Journal of Cancer online.
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1998; Park et al, 2006; Kim et al, 2007), further supporting the idea
that ERBB2 amplification may occur at an early stage in gastric
carcinogenesis.
Our findings indicate that the influence of ERBB2 amplification
on patient survival may differ among histological types and
pathological staging. The overall survival analysis showed little
difference in prognosis according to ERBB2 status (P¼0.222),
which could be explained by the patient heterogeneity regarding
histological and clinical characteristics. According to Ming (1977),
expansive carcinomas grow by enlargement of cohesive tumour
nodules or masses, with a well-defined tumour boundary. On the
other hand, infiltrative carcinomas grow as dispersed, isolated
cells, and clusters or small glands that show a strong invasive
potential with extensive infiltration into the stroma. This
infiltrative characteristic might explain why some authors found
that this type of growth pattern was associated with worse
prognosis (Davessar et al, 1990; Cimerman et al, 1994; Luebke
et al, 2005). Our survival analysis showed that ERBB2-amplifying
expansive carcinomas have worse prognosis than those with the
same growth pattern lacking that genetic alteration (P¼0.011),
which we did not observe in infiltrating gastric carcinomas
(P¼0.863). Recent data published by Wolf-Yadlin et al (2006)
might explain the different effect of ERBB2 amplification in
carcinomas with different growth patterns. These authors sug-
gested that ERBB2 overexpression promotes increased cell
migration but has minimal effect on cell proliferation in cells
stimulated by epidermal growth factor or heregulin (Wolf-Yadlin
et al, 2006). Thus, ERBB2 amplification could increase cell
migration in expansive carcinomas, whereas infiltrative carcino-
mas, which already have a strong invasive potential, do not acquire
additional advantage from ERBB2 amplification. A similar reason-
ing may explain our observation of a trend to worse 10-year
survival among ERBB2-amplified node-negative gastric carcino-
mas, something that was also reported by others in breast
carcinomas (Pauletti et al, 2000).
By studying the largest series of gastric cancer patients so far for
ERBB2 amplification and overexpression, we conclude that ERBB2
status may have clinical significance in subsets of patients and that
further studies are warranted to evaluate whether gastric cancer
patients whose tumours present ERBB2 amplification/overexpres-
sion may benefit from the therapy targeting this surface receptor.
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Table 1 Comparison of clinicopathological findings between FISH
negative and positive gastric carcinomas
ERBB2 amplification
Negative (n¼218) Positive (n¼38) P value
Age (years) 66 (±10.8) 63 (±13.6) NS
NS
Sex
Male 127 (58.3%) 18 (47.4%)
Female 91 (41.7%) 20 (52.6%)
Histopathological classification(s)
Lauren 0.007
Intestinal 121 (55.5%) 31 (81.6%)
Diffuse 63 (28.9%) 3 (7.9%)
Non classified 34 (15.6%) 4 (10.5%)
Carneiro 0.013
Glandular 119 (54.5%) 31 (81.6%)
Isolated cells 62 (28.4%) 3 (7.9%)
Solid 5 (2.3%) 2 (5.3%)
Mixed 28 (12.8%) 2 (5.3%)
Non classified 4 (1.8%)
Ming 0.021
Expansive 56 (26%) 18 (47.4%)
Infiltrative 153 (71.2%) 20 (52.6%)
Mixed 6 (2.8%) —
Venous invasion NS
Positive 147 (68%) 24 (63.2%)
Negative 69 (32%) 14 (36.8%)
Nodal metastases
a NS
N0 73 (34%) 9 (23.7%)
N+ 142 (66%) 29 (76.3%)
Clinical stage
a NS
0–IA 26 (12.1%) 2 (5.3%)
IB 21 (9.8%) 3 (7.9%)
II 41 (19%) 7 (18.4%)
IIIA 50 (23.3%) 10 (26.3%)
IIIB 35 (16.3%) 7 (18.4%)
IV 42 (19.5%) 9 (23.7%)
Type of surgery
a NS
Curative 141 (72.3%) 23 (67.6%)
Palliative 54 (27.7%) 11 (32.4%)
NS¼non significant.
aMissing cases due to lack of clinical information.
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
0 1 22 43 64 86 07 28 49 6 1 0 8 1 2 0
Follow-up (months)
0 1 22 43 64 86 07 28 49 6 1 0 8 1 2 0
Follow-up (months)
P=0.222
P=0.011
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Figure 3 Survival curves of gastric cancer patients, (A) Kaplan–Meier
plot for disease-specific survival of 256 gastric cancer patients according to
ERBB2 amplification status. (B) Kaplan–Meier plot for disease-specific
survival of 75 expansive-type gastric cancer patients according to ERBB2
amplification status.
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